Sensorion SA (EPA: ALSEN)

Market Cap	186.83M
Revenue (ttm)	6.15M
Net Income (ttm)	-23.67M
Shares Out	300.36M
EPS (ttm)	-0.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	59,227
Open	0.618
Previous Close	0.616
Day's Range	0.616 - 0.638
52-Week Range	0.413 - 1.040
Beta	1.29
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 19, 2024

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 57
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALSEN

Financial Performance

In 2023, Sensorion's revenue was 5.57 million, an increase of 12.80% compared to the previous year's 4.93 million. Losses were -22.06 million, -4.94% less than in 2022.